The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users

Journal of Psychopharmacology

Volumn 24, Issue 9, 2010, Pages 1381-1393

  Fagundo, Ana B ^a,b   Cuyàs, Elisabet ^a,b   Verdejo Garcia, Antonio ^a,c   Khymenets, Olha ^a   Langohr, Klaus ^a,d   Martín Santos, Rocio ^a,e   Farré, Magí ^a,b   De La Torre, Rafael ^a,f  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

5 HTT polymorphism; clustering switching scoring; COMT polymorphism; ecstasy (MDMA); verbal fluency

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HTTPLR PROTEIN; 5 HTTVNTR PROTEIN; CANNABIS; CATECHOL METHYLTRANSFERASE; METHIONINE; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; VALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG USE; FEMALE; FRONTAL LOBE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; INFORMATION RETRIEVAL; MALE; PHONEME; PRIORITY JOURNAL; SEMANTICS; SPEECH; SPEECH DISORDER; STRIATE CORTEX; VERBAL FLUENCY;

ADULT; CARRIER STATE; CATECHOL O-METHYLTRANSFERASE; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; HALLUCINOGENS; HUMANS; LINGUISTICS; MALE; MARIJUANA SMOKING; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SPEECH; SPEECH DISORDERS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 77953436128     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109354926     Document Type: Article

References (89)

1. Alfimova MV, Golimbet VE, Gritsenko IK, et al. (2007) Interaction of dopamine system genes and cognitive functions in patients with schizophrenia and their relatives and in healthy subjects from the general population. Neurosci Behav Physiol 37: 643-650.
2. Barnett JH, Scoriels L., Munafo MR (2008) Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry 64: 137-144.
3. Benton AL, Hamsher K. (1983) Multilingual Aphasia Examination. Iowa City: AJA Associates.
4. Bhattachary S., Powell JH (2001) Recreational use of 3,4- methylenedioxymethamphetamine (MDMA) or 'ecstasy': evidence for cognitive impairment. Psychol Med 31: 647-658.
5. Bozikas VP, Kosmidis MH, Karavatos A. (2005) Disproportionate impairment in semantic verbal fluency in schizophrenia: differential deficit in clustering. Schizophr Res 74: 51-59.
6. Buchert R., Thomasius R., Wilke F., et al. (2004) A voxel-based PET investigation of the long-term effects of ''Ecstasy'' consumption on brain serotonin transporters. Am J Psychiatry 161: 1181-1189.
7. Burdick KE, Funke B., Goldberg JF, et al. (2007) COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disord 9: 370-376.
8. Cami J., Farre M., Mas M., et al. (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine (''ecstasy''). psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455-466.
9. Clarke HF, Dalley JW, Crofts HS, Robbins TW, Roberts AC (2004) Cognitive inflexibility after prefrontal serotonin depletion. Science 304: 878-880.
10. Clarke HF, Walker SC, Dalley JW, Robbins TW, Roberts AC (2007) Cognitive inflexibility after prefrontal serotonin depletion is behaviorally and neurochemically specific. Cereb Cortex 17: 18-27.
11. Cowan RL, Lyoo IK, Sung SM, et al. (2003) Reduced cortical gray-matter density in human MDMA (Ecstasy) users: a voxel-based morphometry study. Drug Alcohol Depend 72: 225-235.
12. Chen J., Lipska BK, Halim N., et al. (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT). effects on mRNA, protein, and enzyme activity in post-mortem human brain. Am J Hum Genet 75: 807-821.
13. Dafters RI, Hoshi R., Talbot AC (2004) Contribution of cannabis and MDMA (''ecstasy'') to cognitive changes in long-term polydrug users. Psychopharmacology (Berl) 173: 405-410.
14. Daumann J., Fischermann T., Heekeren K., Henke K., Thron A., Gouzoulis-Mayfrank E. (2005) Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology (Berl) 180: 607-611.
15. Daumann J., Jr, Fischermann T., Heekeren K., Thron A., Gouzoulis-Mayfrank E. (2004) Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study. Biol Psychiatry 56: 349-355.
16. De Gaspari D., Siri C., Di Gioia M., et al. (2006) Clinical correlates and cognitive underpinnings of verbal fluency impairment after chronic subthalamic stimulation in Parkinson's disease. Parkinsonism Relat Disord 12: 289-295.
17. De Sola LS, Miguelez-Pan M., Pena-Casanova J., et al. (2008) Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study. J Psychopharmacol 22: 498-510.
18. De Win MM, De Jeu RA, De Bruin K., et al. (2004) Validity of in vivo [123I]beta-CIT SPECT in detecting MDMA-induced neurotoxicity in rats. Eur Neuropsychopharmacol 14: 185-189.
19. Delis DC, Kramer JH, Kaplan E., et al. (2000) California Verbal Learning Test: Manual (2 nd ed.). San Antonio: Psychological Corporation.
20. Duff-Canning SJ, Leach L., Stuss D., et al. (2004) Diagnostic utility of abbreviated fluency measures in Alzheimer disease and vascular dementia. Neurology 62: 556-562.
21. Duncan J., Owen AM (2000) Common regions of the human frontal lobe recruited by diverse cognitive demands. Trends Neurosci 23: 475-483.
22. Egan MF, Goldberg TE, Kolachana BS, et al. (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98: 6917-6922.
23. Epker MO, Lacritz LH, Munro CC (1999) Comparative analysis of qualitative verbal fluency performance in normal elderly and demented populations. J Clin Exp Neuropsychol 21: 425-434.
24. Fagundo AB, Lopez S., Romero M., Guarch J., Marcos T., Salamero M. (2008) Clustering and switching in semantic fluency: predictors of the development of Alzheimer's disease. Int J Geriatr Psychiatry 23: 1007-1013.
25. Farré M., Abanades S., Roset PN, et al. (2007) Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 323: 954-962.
26. Fisk JE, Montgomery C (2009) Evidence for selective executive function deficits in ecstasy/polydrug users. J Psychopharmacol 23: 40-50.
27. Fisk JE, Sharp CA (2004) Age-related impairment in executive functioning: updating, inhibition, shifting, and access. J Clin Exp Neuropsychol 26: 874-890.
28. Fiskerstrand CE, Lovejoy EA, Quinn JP (1999) An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett 458: 171-174.
29. Fox HC, McLean A., Turner JJ, Parrott AC, Rogers R., Sahakian BJ (2002) Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA (''ecstasy'') polydrug users. Psychopharmacology (Berl) 162: 203-214.
30. Gleissner U., Elger CE (2001) The hippocampal contribution to verbal fluency in patients with temporal lobe epilepsy. Cortex 37: 55-63.
31. Gogos JA, Morgan M., Luine V., et al. (1998) Catechol-O- methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 95: 9991-9996.
32. Goldberg TE, Egan MF, Gscheidle T., et al. (2003) Executive sub-processes in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 60: 889-896.
33. Greenberg BD, Tolliver TJ, Huang SJ, Li Q., Bengel D., Murphy DL (1999) Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 88: 83-87.
34. Heffernan TM, Jarvis H., Rodgers J., Scholey AB, Ling J. (2001) Prospective memory, everyday cognitive failure and central executive function in recreational users of Ecstasy. Hum Psychopharmacol 16: 607-612.
35. Hirshorn EA, Thompson-Schill SL (2006) Role of the left inferior frontal gyrus in covert word retrieval: neural correlates of switching during verbal fluency. Neuropsychologia 44: 2547-2557.
36. Ho AK, Sahakian BJ, Robbins TW, Barker RA, Rosser AE, Hodges JR (2002) Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching. Neuropsychologia 40: 1277-1284.
37. Hranilovic D., Stefulj J., Schwab S., et al. (2004) Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol Psychiatry 55: 1090-1094.
38. Hurks P., Hendriksen M., Vles H., et al. (2004) Verbal fluency over time as a measure of automatic and controlled processing in children with ADHD. Brain Cogn 55: 535-544.
39. Hurks M., Vles H., Hendriksen M., et al. (2006) Semantic category fluency versus initial letter fluency over 60 seconds as a measure of automatic and controlled processing in healthy school-aged children. J Clin Exp Neuropsychol 28: 684-695.
40. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P., Krystal JH (2004) Preliminary evidence of hippocampal dysfunction in adolescent MDMA ('ecstasy') users: possible relationship to neurotoxic effects. Psychopharmacology (Berl) 173: 383-390.
41. Kalechstein AD, De La Garza R., Mahoney JJ, III, Fantegrossi WE, Newton TF (2007) MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl) 189: 531-537.
42. Lamers CT, Bechara A., Rizzo M., Ramaekers JG (2006) Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls. J Psychopharmacol 20: 302-311.
43. Landry MJ (2002) MDMA: a review of epidemiologic data. J Psychoactive Drugs 34: 163-169.
44. Lesch KP, Bengel D., Heils A., et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.
45. Liechti ME, Baumann C., Gamma A., Vollenweider FX (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, ''Ecstasy'') are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22: 513-521.
46. McCann UD, Szabo Z., Scheffel U., Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA (''Ecstasy'') on brain serotonin neurons in human beings. Lancet 352: 1433-1437.
47. McCann UD, Szabo Z., Vranesic M., et al. (2008) Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine (''ecstasy'') users: relationship to cognitive performance. Psychopharmacology (Berl) 200: 439-450.
48. Meyer-Lindenberg A., Kohn PD, Kolachana B., et al. (2005) Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 8: 594-596.
49. Meyer-Lindenberg A., Nichols T., Callicott JH, et al. (2006) Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry 11: 867-877, 797.
50. Miller J. (1990) Discreteness and continuity in models of human information processing. Acta Psychol (Amst) 74: 297-318.
51. Moeller FG, Steinberg JL, Dougherty DM, Narayana PA, Kramer LA, Renshaw PF (2004) Functional MRI study of working memory in MDMA users. Psychopharmacology (Berl) 177: 185-194.
52. Montgomery C., Fisk JE (2008) Ecstasy-related deficits in the updating component of executive processes. Hum Psychopharmacol 23: 495-511.
53. Montgomery C., Fisk JE, Newcombe R., Murphy PN (2005) The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory. Psychopharmacology (Berl) 182: 262-276.
54. Morgan MJ (1998) Recreational use of ''ecstasy'' (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19: 252-264.
55. Morgan MJ (2000) Ecstasy (MDMA). a review of its possible persistent psychological effects. Psychopharmacology (Berl) 152: 230-248.
56. Murphy KJ, Fox GB, Foley AG, et al. (2001) Pentyl-4-yn-valproic acid enhances both spatial and avoidance learning, and attenuates age-related NCAM-mediated neuroplastic decline within the rat medial temporal lobe. J Neurochem 78: 704-714.
57. Nifosi F., Martinuzzi A., Toffanin T., et al. (2008) Hippocampal remodelling after MDMA neurotoxicity: A single case study. World J Biol Psychiatry 29: 1-8.
58. Obrocki J., Buchert R., Vaterlein O., Thomasius R., Beyer W., Schiemann T. (1999) Ecstasy-long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 175: 186-188.
59. Pantel J., Schonknecht P., Essig M., Schroder J. (2004) Distribution of cerebral atrophy assessed by magnetic resonance imaging reflects patterns of neuropsychological deficits in Alzheimer's dementia. Neurosci Lett 361: 17-20.
60. Quednow BB, Jessen F., Kuhn KU, Maier W., Daum I., Wagner M. (2006) Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction. J Psychopharmacol 20: 373-384.
61. Quednow BB, Kühn KU, Hoppe C., et al. (2007) Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA (''Ecstasy''). Psychopharmacology (Berl) 189: 517-530.
62. Ramamoorthy S., Cool DR, Mahesh VB, et al. (1993) Regulation of the human serotonin transporter. Cholera toxin-induced stimulation of serotonin uptake in human placental choriocarcinoma cells is accompanied by increased serotonin transporter mRNA levels and serotonin transporter-specific ligand binding. J Biol Chem 268: 21626-21631.
63. Reneman L., Booij J., De Bruin K., et al. (2001 a) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358: 1864-1869.
64. Reneman L., Lavalaye J., Schmand B., et al. (2001 b) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4- methylenedioxymethamphetamine (MDMA or ''ecstasy''). preliminary findings. Arch Gen Psychiatry 58: 901-906.
65. Reneman L., Schilt T., De Win MM, et al. (2006) Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. J Psychopharmacol 20: 389-399.
66. Rey A. (1941) Psychological examination of traumatic encephalopathy. Archieves de Psychologic 28: 286-340.
67. Riedel WJ, Klaassen T., Deutz NE, Van Someren A., Van Praag HM (1999) Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacology (Berl) 141: 362-369.
68. Rogers RD, Blackshaw AJ, Middleton HC, et al. (1999) Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour. Psychopharmacology (Berl) 146: 482-491.
69. Roiser JP, Cook LJ, Cooper JD, Rubinsztein DC, Sahakian BJ (2005) Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. Am J Psychiatry 162: 609-612.
70. Roiser JP, Rogers RD, Cook LJ, Sahakian BJ (2006) The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls. Psychopharmacology (Berl) 188: 213-227.
71. Rosen VM, Engle RW (1997) The role of working memory capacity in retrieval. J Exp Psychol 126: 211-227.
72. Shallice T. (1982) Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci 25: 199-209.
73. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 175: 63-69.
74. Smith RA (1982) Symbol Digit Modalities Test (SDMT) Manual (Revised). Los Angeles: Western Psychological Services.
75. Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., Catalano M. (1998) Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3: 508-511.
76. Sumiyoshi C., Sumiyoshi T., Nohara S., et al. (2005) Disorganization of semantic memory underlies alogia in schizophrenia: an analysis of verbal fluency performance in Japanese subjects. Schizophr Res 74: 91-100.
77. Sumiyoshi C., Sumiyoshi T., Roy A., Jayathilake K., Meltzer HY (2006) Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia. Int J Neuropsychopharmacol 9: 677-683.
78. Torrens M., Serrano D., Astals M., Pérez-Domínguez G., MartínSantos R. (2004) Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 161: 1231-1237.
79. Troster AI, Fields JA, Testa JA, et al. (1998) Cortical and subcortical influences on clustering and switching in the performance of verbal fluency tasks. Neuropsychologia 36: 295-304.
80. Troyer AK (2000) Normative data for clustering and switching on verbal fluency tasks. J Clin Exp Neuropsychol 22: 370-378.
81. Troyer AK, Moscovitch M., Winocur G. (1997) Clustering and switching as two components of verbal fluency: evidence from younger and older healthy adults. Neuropsychology 11: 138-146.
82. Troyer AK, Moscovitch M., Winocur G., Alexander MP, Stuss D. (1998) Clustering and switching on verbal fluency: the effects of focal frontal- and temporal-lobe lesions. Neuropsychologia 36: 499-504.
83. Von Geusau NA, Stalenhoef P., Huizinga M., Snel J., Ridderinkhof KR (2004) Impaired executive function in male MDMA (''ecstasy'') users. Psychopharmacology (Berl) 175: 331-341.
84. Wechsler D. (1997) WAIS-III and WMS-III Technical Manual. San Antonio: The Psychological Corporation.
85. Whale R., Quested DJ, Laver D., Harrison PJ, Cowen PJ (2000) Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology (Berl) 150: 120-122.
86. Woodward ND, Jayathilake K., Meltzer HY (2007) COMT val108/ 158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 90: 86-96.
87. Yip JT, Lee TM (2005) Effect of ecstasy use on neuropsychological function: a study in Hong Kong. Psychopharmacology (Berl) 179: 620-628.
88. Zakzanis KK, Young DA (2001) Executive function in abstinent MDMA ('ecstasy') users. Med Sci Monit 7: 1292-1298.
89. Zakzanis KK, Campbell Z., Jovanovski D. (2007) The neuropsychology of ecstasy (MDMA) use: a quantitative review. Hum Psychopharmacol 22: 427-435.